Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: A case report

Clinical Pharmacology and Therapeutics

Volumn 53, Issue 1, 1993, Pages 89-95

  Bluhm, Renata E ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DAPSONE; DEBRISOQUINE; DESIPRAMINE; DRUG METABOLITE; MEPHENYTOIN;

ADULT; ARTICLE; CARDIOTOXICITY; CASE REPORT; DEPRESSION; DRUG BLOOD LEVEL; DRUG METABOLISM; ELECTROCARDIOGRAM; GENETIC AND FAMILIAL DISORDERS; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL;

ACETYLATION; CASE REPORT; DEBRISOQUIN; DEPRESSIVE DISORDER; DESIPRAMINE; ELECTROCARDIOGRAPHY; FAMILY; GENETIC SCREENING; HEART DISEASES; HUMAN; MALE; MIDDLE AGE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027471030     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1038/clpt.1993.13     Document Type: Article

References (11)

1. Brosen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. CLIN PHARMACOL THER 1991;49:609-17.
2. Bertilsson L, Aberg-Wistedt A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983;15:388-90.
3. Classman AH, Pardell R, Woodring S. Cardiovascular effects of the standard tricyclic antidepressants. Clin Chem 1988;34:856-8.
4. Burckhardt D, Raeder E, Muller V, Imhof P, Neubauer H. Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA 1978;239:213-6.
5. Guengerich FP. Characterization of human cytochrome P450 enzymes. FASEB J 1992;6:745-748.
6. Fleming C, Branch RA, Wilkinson GR, Guengenrich P. Human liver microsomal W-hydroxylation of dapsone by cytochrome P4503A4. Mol Pharmacol 1992;41: 975-80.
7. Can K, Oates JA, Nies AS, Woosley RL. Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br J Clin Pharmacol 1978;6:421-7.
8. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Deficiency of mephenytoin hydroxylation in a Caucasian population: frequency of a new oxidative drug metabolism polymorphism. CLIN PHARMACOL THER 1984;36:773-80.
9. Kupfer A, Desmond P, Patwardhan R, Schenker S, Branch RA. Mephenytoin hydroxylation deficiency: kinetics after repeated doses. CLIN PHARMACOL THER 1984;35:33-9.
10. Kupfer A, Roberts RK, Schenker S, Branch RA. Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther 1981;218:193-9.
11. May DO, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA. The contribution of W-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. CLIN PHARMACOL THER 1990;48:619-27.